Our pooled results demonstrated that the use of anti-VEGF agents did not significantly improved OS in elderly HCC patients giving HR of 0.87 (95% CI: 0.73–1.05, p = 0.15 Figure 3). Here, VEGFA is linked to hepatocellular carcinoma.